We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Topiramate for Weight Loss in Subjects With Metabolic Syndrome

This study has suspended participant recruitment.
(Study was discontinued because of high drop out rate.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00243984
First Posted: October 25, 2005
Last Update Posted: December 10, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Akron General Medical Center
Forum Health
Aultman Health Foundation
St. Elizabeth Health Center
Mercy Medical Center
Information provided by:
Northeastern Ohio Universities College of Medicine
  Purpose
The purpose of this study is to evaluate the efficacy of topiramate compared to placebo in the treatment of obesity in metabolic syndrome. Secondary objectives include topiramate and weight loss effects on lipid levels, HbA1C, insulin resistance, and blood pressure.

Condition Intervention Phase
Metabolic Syndrome X Diabetes Mellitus, Type 2 Drug: topiramate Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Efficacy of Topiramate for Weight Loss in Subjects With Metabolic Syndrome

Resource links provided by NLM:


Further study details as provided by Northeastern Ohio Universities College of Medicine:

Primary Outcome Measures:
  • Change in weight on days 28, 56, 84, 112, 140, 168, and 175.
  • Waist circumference on days 1, 84 and 168.
  • BMI on days 1, 84, 168, and 175.

Secondary Outcome Measures:
  • Blood pressure on days 1, 28, 56, 84, 112, 140, 168, and 175.
  • Complete metabolic profile on days 84 and 168.
  • HbA1C on days 1, 84, and 168.
  • Lipid profile on days 84 and 168.
  • C reactive protein on days 1, 84, and 168.

Estimated Enrollment: 90
Study Start Date: March 2005
Estimated Study Completion Date: November 2007
Detailed Description:

Topiramate is an anti-convulsant which has been approved for use as adjunctive treatment for partial-onset seizures, Lennox-Gastaut syndrome, or primary generalized tonic-clonic seizures. Topiramate is currently under investigation for other disorders including binge-eating disorder.

Metabolic syndrome is a constellation of findings which includes dyslipidemia, abdominal obesity, hyperglycemia, and hypertension. Insulin resistance is believed to be the cause whereby obesity increases resistance to insulin. Weight loss in type 2 diabetics is known to reduce insulin resistance and allow for greater glycemic control. Weight loss in pre-diabetics can often forstall the development of diabetes. Additionally, aggressive blood pressure control in diabetics reduces the risk of coronary artery disease. Weight loss reduces blood pressure and is used as first line treatment for hypertension.

Comparison: Patients who meet the criteria for metabolic syndrome and prescribed topiramate will be compared with those patients who meet the same criteria and are prescribed placebo.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Metabolic Syndrome
  • BMI >/=30kg/m2
  • and 3 of the 5 following criteria:

    1. Triglycerides >/=150mg/dl
    2. HDL cholesterol </=40mg/dl (men) or </=50mg/dl (women)
    3. Blood pressure > 130/85
    4. Waist circumference >/=40inches (men) or >/=35inches (women)
    5. Fasting blood glucose >/=110mg/dl or diagnosis of type 2 diabetes mellitus
  • Able to give informed consent
  • Diabetes Mellitus must be well controlled for the past 3 months and HbA1c </=9.0
  • Hypertension must be well controlled for the past 3 months and BP <140/90
  • Willing and able to take oral medication
  • Female subjects must be post menopausal for 1 year, surgically sterile, or practicing an effective method of birth control; and have a negative monthly pregnancy test at screening and throughout the study.

Exclusion Criteria:

  • Any person unable to take topiramate
  • Renal insufficiency
  • Taking medication with known serious interactions with topiramate
  • History of psychosis, epilepsy or any other disease in which taking topiramate may interfere with treatment of that disease
  • Positive urine drug screen
  • Previous treatment with topiramate and subsequent adverse event; or concurrent treatment with topiramate
  • History of nephrolithiasis
  • Pregnancy or lactating
  • Subjects who are members of the same household
  • Currently on an exercise or diet plan
  • Bariatric surgery within the past 5 years
  • Clinically significant medical conditions including (but not limited to) symptomatic coronary artery disease or peripheral vascular disease, or taking nitrates; malignancy or history of malignancy within the past 5 years (except basal cell carcinoma); Impaired renal function as defined by an estimated creatinine clearance </=60ml/min; Gastrointestinal system diseases including active liver disease; ALT or AST>2 times the upper limit of normal; Pulmonary disorders; Endocrine disorders except for well controlled diabetes mellitus and hypothyroidism; Any disease or condition that compromises the function of those body systems that could result in altered absorption, excess accumulation, or impaired metabolism or excretion of topiramate.
  • Subjects who in the opinion of the investigator should not be enrolled in the study because of the precautions, warnings, or contraindications sections of the topiramate package insert
  • Family members of employees or investigators and employees of the investigator or study center may participate but may not serve any staff role for themselves.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00243984


Locations
United States, Ohio
Akron General Medical Center
Akron, Ohio, United States, 44307
Mercy Medical Center
Canton, Ohio, United States, 44708
Aultman Hospital
Canton, Ohio, United States, 44710
Forum Health/Northside Medical Center
Youngstown, Ohio, United States, 44501
St. Elizabeth Health Center
Youngstown, Ohio, United States, 44501
Sponsors and Collaborators
Northeastern Ohio Universities College of Medicine
Akron General Medical Center
Forum Health
Aultman Health Foundation
St. Elizabeth Health Center
Mercy Medical Center
Investigators
Principal Investigator: Frederick Whittier, MD Northeastern Ohio Universities College of Medicine
  More Information

ClinicalTrials.gov Identifier: NCT00243984     History of Changes
Other Study ID Numbers: 05005
First Submitted: October 21, 2005
First Posted: October 25, 2005
Last Update Posted: December 10, 2007
Last Verified: December 2007

Keywords provided by Northeastern Ohio Universities College of Medicine:
metabolic syndrome
type 2 diabetes
topiramate
weight loss

Additional relevant MeSH terms:
Syndrome
Diabetes Mellitus
Weight Loss
Metabolic Syndrome X
Diabetes Mellitus, Type 2
Disease
Pathologic Processes
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Body Weight Changes
Body Weight
Signs and Symptoms
Insulin Resistance
Hyperinsulinism
Topiramate
Anticonvulsants
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs
Anti-Obesity Agents